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Cardiac pacemaker channel 
(HCN4) inhibition and atrial 
arrhythmogenesis after releasing 
cardiac sympathetic activation
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Marcus May  4, Heidrun Mehling5, Friedrich C. Luft5, Christoph Schröder1, Jens Jordan1,2 & 
Jens Tank  1,2
Clinical trials and studies with ivabradine implicate cardiac pacemaker channels (HCN4) in the 
pathogenesis of atrial arrhythmias. Because acute changes in cardiac autonomic tone predispose to 
atrial arrhythmias, we studied humans in whom profound cardiac sympathetic activation was rapidly 
relieved to test influences of HCN4 inhibition with ivabradine on atrial arrhythmias. We tested 19 
healthy participants with ivabradine, metoprolol, or placebo in a double blind, randomized, cross-over 
fashion on top of selective norepinephrine reuptake inhibition with reboxetine. Subjects underwent 
combined head up tilt plus lower body negative pressure testing followed by rapid return to the 
supine position. In the current secondary analysis with predefined endpoints before data unblinding, 
continuous finger blood pressure and ECG recordings were analyzed by two experienced cardiac 
electrophysiologists and a physician, blinded for treatment assignment. The total atrial premature 
activity (referred to as atrial events) at baseline did not differ between treatments. After backwards 
tilting, atrial events were significantly higher with ivabradine compared with metoprolol or with 
placebo. Unlike beta-adrenoreceptor blockade, HCN4 inhibition while lowering heart rate does not 
protect from atrial arrhythmias under conditions of experimental cardiac sympathetic activation. The 
model in addition to providing insight in the role of HCN4 in human atrial arrhythmogenesis may have 
utility in gauging potential atrial pro-arrhythmic drug properties.
Sympathetic and parasympathetic nervous system mechanisms are implicated in atrial arrhythmias. While para-
sympathetic activation promotes atrial arrhythmias in younger healthy individuals, adrenergic mechanisms may 
prevail in older individuals with cardiovascular disease1. Rapid fluctuations in cardiac autonomic tone potently 
promote atrial arrhythmias. Patients with focal ectopy originating from pulmonary veins exhibited transition 
from cardiac sympathetic to parasympathetic predominance just before paroxysmal atrial fibrillation onset2. 
Similarly, transitory cholinergic stimulations on top of pharmacological beta-adrenoreceptor stimulation elic-
ited atrial tachyarrhythmia in isolated canine atrial preparations3. In contrast, vagal withdrawal preceded atrial 
fibrillation following coronary artery bypass surgery4. We established a human model of rapid cardiac vagal acti-
vation during profound cardiac sympathetic activation. Cardiac sympathetic activation is achieved through com-
bined selective norepinephrine transporter inhibition and head-up tilt testing with lower body negative pressure. 
Rapid tilting back to the supine position acutely augments cardiac vagal activity while attenuating sympathetic 
drive. We applied the model in a placebo controlled, double blind, crossover study to test the hypothesis that 
hyperpolarization-activated and cyclic nucleotide-gated 4 (HCN4) channel inhibition with ivabradine promotes 
atrial arrhythmogenesis in healthy individuals. In clinical trials, atrial fibrillation was more likely to occur in 
ivabradine compared with placebo treated patients5,6. Moreover, trafficking-defective mutations in HCN4 gene 
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predispose to early-onset atrial fibrillation7. Beta-adrenoreceptor blockade, which in addition to lowering heart 
rate attenuates adrenergic influences on atrial and ventricular myocardial cells, served as control intervention.
Results
Heart rate and blood pressure responses at the end of the head-up tilt protocol and the transition to the supine 
recovery phase are shown in Fig. 1. Combination of norepinephrine transporter inhibition and severe orthostatic 
stress resulted in substantial tachycardia that was attenuated by, both, metoprolol, and ivabradine. Return to the 
supine position led to rapid heart rate and blood pressure recovery regardless of treatment.
During the five minutes recovery phase following orthostatic testing, atrial events were significantly more 
frequent and more pronounced with ivabradine compared with metoprolol or with placebo (Fig. 2). Six par-
ticipants out of 19 showed a particularly prominent response to ivabradine. Of those, three were allocated to 
the treatment sequence metoprolol-placebo-ivabradine, two to ivabradine-placebo-metoprolol, and one to 
placebo-ivabradine-metoprolol. Thus, the arrhythmogenic effect of ivabradine was not restricted to one particu-
lar treatment sequence. Yet, a significant sequence effect cannot be excluded given the low number of participants 
in each treatment sequence. Two participants showed numerically higher atrial events on placebo day than on 
ivabradine. One participant developed more atrial events on metoprolol than on placebo and ivabradine.
When atrial arrhythmias were observed separately as atrial premature beats and atrial runs, statistically signif-
icant difference was seen in the number of atrial runs between ivabradine and metoprolol treatment (P < 0.001; 
Figure 1. Hemodynamics during transition from head-up tilt (HUT) to the supine position. Ivabradine (IVA), 
metoprolol (MET) and placebo (PLC).
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Fig. 2). Figure 3 shows ECG recordings during the recovery period on ivabradine, on metoprolol, and on placebo 
in a participant experiencing the highest number of atrial arrhythmias. The number of atrial premature beats was 
numerically higher with ivabradine compared to metoprolol and placebo (Table 1), the group difference was not 
statistically significant (P = 0.071 for all treatments). In contrast, we observed no clinically relevant or statistically 
significant differences in atrial or ventricular arrhythmia rates between treatments in the supine baseline period 
before orthostatic testing, although numerically more atrial events were counted on placebo and on ivabradine 
compared with metoprolol (Table 1). No differences in other arrhythmia types at baseline or after tilting back 
were observed. Table 1 summarizes the number of arrhythmic events in all three study occasions.
Discussion
The important finding of our study is that selective HCN4 inhibition with ivabradine increases atrial arrhythmic 
event rate compared with the beta-adrenoreceptor blocker metoprolol or with placebo during transition from 
profound cardiac sympathetic activation to sympathetic withdrawal and cardiac vagal activation. In addition to 
introducing a novel model for human drug research, our study may have implications for the clinical use of HCN4 
inhibitors and provide insight in the role of this channel in the pathophysiology of human atrial arrhythmias.
Combined norepinephrine transporter inhibition and orthostatic stress produced profound cardiac sym-
pathetic activation8,9. Sympathetic withdrawal and cardiac vagal activation was elicited by rapidly tilting sub-
jects back to the supine position. In peripheral tissues, norepinephrine transporter inhibition tends to increase 
Figure 2. Atrial events, atrial premature beats and atrial runs after tilting back (recovery) as individual scatter 
plots (left panels) and after correction to baseline (BL) with ivabradine (IVA), metoprolol (MET) and placebo 
(PLC) (right panels).
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norepinephrine availability10. Conversely, norepinephrine transporter inhibition decreases sympathetic outflow 
from the brain11,12. Overall, sympathetic activity is redistributed towards the heart13,14. Therefore, orthostatic tach-
ycardia is a hallmark of pharmacological norepinephrine transporter inhibition9,15 and familial norepinephrine 
transporter dysfunction16. Yet, baroreflex heart rate regulation is maintained such that baroreflex unloading with 
return to the supine position rapidly reduced heart rate8,17. Given the transmission characteristics of efferent vagal 
and sympathetic fibers, vagal activation may have preceded sympathetic withdrawal during this phase. While 
heart rate variability measurements provide additional insight in autonomic control mechanisms, we opted not to 
conduct this analysis given the large number of arrhythmic events and the non-steady-state conditions.
Our findings confirm and extend observations in genetic conditions associated with altered HCN4 function 
and clinical trials with the HCN4 blocker ivabradine18,19. Rare HCN4 gene mutations have been identified in 
patients with familial bradycardia and atrial fibrillation19,20. Trafficking-defective, loss of function mutations in 
the HCN4 gene predispose to early-onset atrial fibrillation in individuals with healthy hearts7. Furthermore, 
ivabradine treatment predisposed to atrial fibrillation compared with placebo treated patients5,6. Conversely, iva-
bradine on top of beta-adrenoreceptor blockade appeared to be beneficial in patients with atrial fibrillation in 
smaller studies21,22. Our study suggests that HCN4’s full atrial arrhythmogenic potential may be revealed during 
transition from cardiac sympathetic activation to vagal predominance.
Both autonomic nervous system branches affect cardiac arrhythmogenicity in a complex fashion1–4. For exam-
ple, vagotonic maneuvers trigger atrial arrhythmias in susceptible individuals23,24. Influences of cardiovascular 
medications on cardiac arrhythmias during changes of cardiac autonomic tone may go undetected during routine 
clinical development, particularly in early stage clinical trials in healthy persons.
Differential effects of metoprolol and ivabradine on atrial arrhythmogenicity likely result from drug specific 
interactions with cardiac autonomic drive and influences on endogenous rhythm generation. Beta-adrenoreceptor 
blockade attenuates sympathetic influences on sinus node, conduction system, and atrial and ventricular 
Figure 3. ECG recordings of the participant who experienced the highest number of atrial premature beats 
after tilting back in all three treatment occasions: (A) in the baseline supine position on the ivabradine day; (B–
D) tilting back from head-up tilt into supine position on ivabradine (B), metoprolol (C), and placebo (D) days.
Day
Atrial events Atrial premature beats Atrial runs Ventricular premature beats
Baseline Recovery Baseline Recovery Baseline Recovery Baseline Recovery
IVA 4 (98) 19 (770) 4 (75) 19 (326) 2 (5) 15 (101) 1 (2) 4 (82)
MET 1 (23) 16 (190) 1 (14) 16 (160) 1 (2) 5 (7) 0 (0) 1 (3)
PLC 6 (131) 17 (413) 6 (92) 17 (225) 3 (5) 13 (44) 0 (0) 3 (60)
Table 1. The number of subjects with atrial events, atrial premature beats, atrial runs and ventricular premature 
beats on different study days at supine baseline and after tilting back (recovery) and the number of respective 
arrhythmic events per study occasion (in parenthesis). IVA, ivabradine; MET, metoprolol; PLC, placebo.
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cardiomyocytes. Ivabradine, which binds to the open HCN4 channel25,26, selectively slows sinus node diastolic 
depolarization while leaving sympathetic activation elsewhere in the heart unopposed8,17. Aggravated brady-
cardia during baroreflex loading suggested that ivabradine might also augment vagal influences on the sinus 
node17. Furthermore, HCN4 appears to serve as defense mechanism against bradycardia and to stabilize cardiac 
rhythm27.
Overall, we propose that ivabradine-induced arrhythmogenesis may be explained at least in part by unop-
posed cardiac sympathetic activation obscured by sinus rate reduction. In addition, we speculate that HCN4 
inhibition might perturb the fine interplay and synchronization between membrane and calcium clocks involved 
in cardiac pacemaking28–30.
A potential limitation of our study is that for practical reasons, particularly ethically acceptable treatment 
duration in healthy persons, test drugs were not in steady state. Yet, we previously showed that we achieved drug 
concentrations in a clinically relevant range8. Nevertheless, our findings should not be simply extrapolated to 
patients chronically treated with these drugs. Furthermore, we retrospectively analyzed data collected during a 
clinical trial. We attempted to minimize potential sources of bias by prospectively defining study endpoints as 
well as the statistical analysis plan before data was compiled and analyzed and by blinding investigators rating 
ECG tracings.
We conclude that HCN4 inhibition with ivabradine, compared with beta-adrenoreceptor blocker metoprolol, 
while lowering heart rate did not protect from atrial arrhythmias during transition from cardiac sympathetic 
activation to vagal predominance. Our approach of combining pharmacological and physiological methodologies 
eliciting rapid and profound changes in cardiac autonomic tone may have utility in testing the atrial arrhythmo-
genicity of drugs. In patients with heart failure or angina pectoris, ivabradine is commonly prescribed on top 
of beta-adrenoreceptor blockade. The clinical implication of our study is that patients treated with ivabradine 
without beta-adrenoreceptor blockade may require intensified monitoring for atrial arrhythmias. Additionally, 
beta-adrenoreceptor blockers may be necessary to prevent ivabradine-induced cardiac rhythm derangements in 
certain patients with high risk for or already overt atrial arrhythmia. The issue may be particularly relevant for 
patients with postural tachycardia syndrome who feature orthostatic heart rate responses with standing that are 
almost identical to those observed on norepinephrine transporter inhibition in our study.
Methods
Study participants. We conducted an observer-blinded, prospectively planned, secondary analysis of data 
previously obtained in a mechanism-oriented clinical investigation (clinicaltrials.gov: NCT00865917)8. The study 
was performed in accordance with the Declaration of Helsinki and approved by the national competent author-
ity and local institutional review boards (the ethics committee of Charité – Universitätsmedizin Berlin as well 
as the ethics committee of Hannover Medical School). Nineteen healthy normotensive men (18–40 years, BMI 
18–30 kg/m2, resting heart rate >55 bpm) were included after written informed consent had been obtained.
Protocol. The protocol has been described previously8. Briefly, in a randomized, double-blind, three-period, 
six-sequence crossover fashion, subjects ingested maximal recommended doses of metoprolol (95 mg), ivabradine 
(7.5 mg), or placebo 13 h and 1 h before testing on three separate study days. In addition, participants ingested 
4 mg of selective norepinephrine transporter inhibitor reboxetine (Edronax, Pfizer, Karlsruhe, Germany) 13 h and 
1 h before testing as background medication on all three study days. The washout period between measurements 
was at least 2 weeks to prevent carry over effects.
Cardiovascular testing was conducted between 08:00 and 11:00 a.m. in a quiet laboratory at an ambi-
ent temperature of 22–23 °C. Heart rate was continuously monitored by electrocardiogram (ECG, Viridia, 
Hewlett-Packard). Beat-to-beat finger blood pressure was continuously registered by volume-clamp photople-
thysmography (2300 Finapres, Ohmeda, Madison, WI) with the finger kept at the heart level throughout the 
experiment. After instrumentation, subjects remained supine for 30 min for baseline recordings. Head-up tilt 
was started with a graded initial phase during which the tilt angle was increased by 15° every 2 min up to a tilt 
angle of 60°, at which subjects remained for 20 min. With the subjects remaining at 60° head-up tilt, additional 
orthostatic stress was applied stepwise using lower body negative pressure of −20 and −40 mm Hg for 10 minutes 
each. The complete head-up tilt protocol lasted up to 46 minutes. The test was aborted when subjects experienced 
hypotension or presyncopal symptoms. At the end of the test, lower body negative pressure was switched off and 
subjects were rapidly returned to the supine position. Thereafter, recordings were continued during the recovery 
period for another five minutes.
Data acquisition and analysis. ECG and continuous finger blood pressure signals were recorded at 
500 Hz using the Windaq pro+ software (Dataq Instruments, Akron, OH). Five-minute ECG recordings dur-
ing supine baseline and after tilting back were first analyzed by two experienced cardiac electrophysiologists 
(DD, CV). Discrepancies were resolved through discussion with another physician experienced in ECG analysis 
(KCJ). Evaluators were blinded for patient and treatment. Premature atrial and ventricular beats were assessed. 
An atrial or ventricular run was defined as 4–7 successive premature beats. An ectopic rhythm was defined as a 
P wave showing a differing morphology and/or sudden jump in cycle length compared to P wave morphology 
or cycle length during sinus rhythm. Sinus arrest was present when regular ventricular rhythm without P waves 
was identified. An atrioventricular (AV) block was registered when AV dissociation was detected. Arrhythmias 
were counted per minute as well as for the entire five minutes interval. Different counts between evaluators were 
reconciled by averaging and rounding up. The total atrial premature activity was accounted as the sum of single 
premature atrial events and all events during an atrial run.
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Endpoint and statistical analysis. Exploratory endpoints were defined and the statistical analysis 
approach was finalized before the analysis was unblinded. Our exploratory endpoints include the total number 
of atrial arrhythmic premature events over five min observation period after tilting back (further referred as 
atrial events), the number of arrhythmic events during supine baseline, and the difference between the counts of 
arrhythmic events after tilting back corrected to the arrhythmic events during supine baseline (delta). D’Agostino 
and Pearson omnibus normality test was applied for data distribution testing. The non-parametric Friedman 
test comparing paired groups together with Dunn’s post hoc test for multiple comparisons were used to test the 
differences in the arrhythmic events rate between the treatments (ivabradine vs. metoprolol vs. placebo) as well as 
between visit days (visit 1 vs. visit 2 vs. visit 3, treatment-independent One-way analysis of variance (ANOVA)). 
Potential influence of sequence administration on atrial arrhythmogenicity was considered. P values < 0.05 were 
considered statistically significant. Data are presented as median [25th, 75th percentile] (for arrhythmic events) 
and as mean ± SEM (for hemodynamic parameters), respectively. All analyses were performed using GraphPad 
Prism version 5.00 for Windows, GraphPad Software, San Diego, California, USA.
Data Availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
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